Printer Friendly

MISCOLL, MANATT NAMED TO SPI PHARMACEUTICAL'S BOARD

 MISCOLL, MANATT NAMED TO SPI PHARMACEUTICAL'S BOARD
 COSTA MESA, Calif., April 23 /PRNewswire/ -- James P. Miscoll,


retiring vice chairman of BankAmerica Corp., San Francisco, and Charles T. Manatt, a Los Angeles attorney of national prominence, have been elected to the board of directors of SPI Pharmaceuticals Inc. (AMEX: SPI).
 "We're privileged to have these men with broad business and financial experience join our board," said Milan Panic, chairman and chief executive officer of SPI.
 During Miscoll's 30-year career, he has headed up operations in Europe,


Asia and Australia. For the past seven years, Miscoll has been executive officer of Southern California operations. He has been a member of the bank's managing committee for the 10 years.
 A graduate of Marquette University and University of Wisconsin, Miscoll is also a graduate of Harvard and Northwestern Universities' Advanced Management Programs. He has three grown children and lives in Los Angeles.
 In 1964, Manatt began a law practice specializing in banking law. Today, the firm has more than 125 attorneys in offices in Los Angeles and Washington, D.C.
 Manatt was chairman of the Democratic National Committee from 1981 through 1985. He has served on the board of directors of the Los Angeles Performing Arts Council and as chairman of the board of counselors of the University of Southern California School of Public Administration.
 A graduate of George Washington University Law School in 1962, Manatt is married to the former Kathleen Klinkefus. They have three children.
 SPI Pharmaceuticals Inc., headquartered in Costa Mesa, manufactures, markets and distributes 600 prescription and non-prescription pharmaceuticals in over 60 countries, including North and Latin America, Western and Eastern Europe, and the Far East.
 -0- 4/23/92
 /CONTACT: Paul Knopick of SPI Pharmaceuticals Inc., 714-545-0100, ext. 2465/
 (SPI) CO: SPI Pharmaceuticals Inc. ST: California IN: MTC SU: PER


SE-KJ -- LA039 -- 2127 04/23/92 16:37 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 23, 1992
Words:310
Previous Article:SFFED RELEASES APRIL CONSOLIDATED FINANCIAL HIGHLIGHTS
Next Article:ORNDA HEALTHCORP ANNOUNCES $400,000,000 NOTES OFFERING AND COMMITMENT FOR NEW CREDIT AGREEMENT WITH G.E. CAPITAL CORPORATION


Related Articles
SPI PHARMACEUTICALS DECLARES 25 CENTS-A-SHARE COMMON STOCK DIVIDEND
SPI PHARMACEUTICALS INC. INCREASES ANNUAL DIVIDEND 6 PERCENT FOR 1992; ADOPTS DIVIDEND REINVESTMENT PROGRAM AND DECLARES FIRST QUARTER DIVIDEND
SPI PHARMACEUTICALS, INC. DECLARES SECOND QUARTER DIVIDEND
ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
RYKOFF-SEXTON ELECTS MISCOLL TO BOARD OF DIRECTORS
SPI PHARMACEUTICALS INC. DECLARES THIRD QUARTER DIVIDEND
/C O R R E C T I O N - SPI PHARMACEUTICALS/
SPI PHARMACEUTICALS, OKTYABR PHARMACEUTICAL FACTORIES AGREE TO FORM NEW VENTURE COMPANY IN ST. PETERSBURG
SPI PHARMACEUTICALS DECLARES FOURTH QUARTER STOCK DIVIDEND EQUIVALENT TO TWENTY CENTS A SHARE
SPI PHARMACEUTICALS DECLARES FOURTH QUARTER STOCK DIVIDEND EQUIVALENT TO 20 CENTS A SHARE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters